Restoration of response to ruxolitinib upon brief withdrawal in two patients with myelofibrosis

Am J Hematol. 2014 Mar;89(3):344-6. doi: 10.1002/ajh.23637.
No abstract available

Publication types

  • Case Reports
  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Drug Administration Schedule
  • Drug Resistance
  • Female
  • Humans
  • Janus Kinase 2 / antagonists & inhibitors
  • Janus Kinase 2 / genetics
  • Middle Aged
  • Nitriles
  • Organ Size / drug effects
  • Polycythemia Vera / complications
  • Primary Myelofibrosis / drug therapy*
  • Primary Myelofibrosis / enzymology
  • Primary Myelofibrosis / etiology
  • Protein Kinase Inhibitors / administration & dosage*
  • Protein Kinase Inhibitors / pharmacology
  • Protein Kinase Inhibitors / therapeutic use
  • Pyrazoles / administration & dosage*
  • Pyrazoles / pharmacology
  • Pyrazoles / therapeutic use
  • Pyrimidines
  • Splenomegaly / drug therapy
  • Splenomegaly / etiology
  • Withholding Treatment

Substances

  • Nitriles
  • Protein Kinase Inhibitors
  • Pyrazoles
  • Pyrimidines
  • ruxolitinib
  • JAK2 protein, human
  • Janus Kinase 2